• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Celldex Therapeutics Inc.

    6/6/25 4:01:59 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email
    S-8 1 tm2517084d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 6, 2025

    Registration No. 333- [     ]

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    CELLDEX THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   13-3191702
    (State or other jurisdiction   (I.R.S. employer
    of incorporation or organization)   identification number)

     

    Perryville III Building

    53 Frontage Road, Suite 220

    Hampton, New Jersey 08827

    (908) 200-7500

    (Address of principal executive offices; zip code)

     

    Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan

    (Full title of the plan)

     

    Sam Martin

    Chief Financial Officer

    CELLDEX THERAPEUTICS, INC.

    Perryville III Building

    53 Frontage Road, Suite 220

    Hampton, New Jersey 08827

    (908) 200-7500

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Anthony O. Pergola, Esq.

    Lowenstein Sandler LLP

    1251 Avenue of the Americas

    New York, New York 10020

    (212) 262-6700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed by the registrant, Celldex Therapeutics, Inc. (the “Company”), for the purpose of registering an additional 2,000,000 shares of common stock, par value $0.001 per share (“Common Stock”), to be issued under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 5, 2025) (the “2021 Plan”), pursuant to General Instruction E on Form S-8 (Registration of Additional Securities).

     

    The contents of the original registration statement on Form S-8 for the 2021 Plan filed on June 16, 2021 (File No. 333-257137), the registration statement on Form S-8 for the 2021 Plan filed on June 21, 2023 (File No. 333-272804) and the registration statement on Form S-8 for the 2021 Plan filed on June 14, 2024 (File No. 333-280207) are hereby incorporated by reference and made a part hereof. Any items in the Company’s Registration Statements on Form S-8 (File No. 333-257137, File No. 333-272804 and File No. 333-280207) not expressly changed hereby shall be as set forth in the Company’s Registration Statements on Form S-8 (File No. 333-257137, File No. 333-272804 and File No. 333-280207). The stockholders of the registrant approved amending the 2021 Plan for this purpose at the annual meeting of stockholders held on June 5, 2025.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Certain Documents by Reference

     

    The Securities and Exchange Commission allows us to “incorporate” into this registration statement information we file with other documents. This means that we may disclose important information to you by referring to other documents that contain that information. The information incorporated by reference is considered to be part of this registration statement, and information we file later with the Securities and Exchange Commission will automatically update and supersede this information. We incorporate by reference the documents listed below, except to the extent information in those documents is different from the information contained in this registration statement:

     

      · Our Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 27, 2025.

     

      · Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed on May 8, 2025.

     

      · Our Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2025 (except to the extent furnished but not filed).
         
      · Our Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 21, 2025 (solely with respect to those portions incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2024).

     

      · The description of the securities contained in the Company’s Registration Statement on Form 8-A filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as the description therein has been updated and superseded by the description of the Company’s capital stock contained in Exhibit 4.3 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on February 28, 2023, including any amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by us with the Securities and Exchange Commission pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this registration statement, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    Item 8. Exhibits

     

    The exhibits accompanying this registration statement are listed on the accompanying exhibit index.

     

    -2-

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
         
    5.1   Opinion of Lowenstein Sandler LLP*
    23.1   Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm of Celldex Therapeutics, Inc.*
    23.2   Consent of Lowenstein Sandler LLP (filed as part of Exhibit 5.1).*
    24.1   Power of Attorney (contained on signature page to this registration statement on Form S-8)*
    99.1   Amendment No. 3 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 6, 2025)
    107   Filing Fee Table*

     

    * Filed herewith.

     

    -3-

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hampton, State of New Jersey, on June 6, 2025.

     

    CELLDEX THERAPEUTICS, INC.  
       
    By: /s/ Anthony S. Marucci  
      Anthony S. Marucci  
      President and Chief Executive Officer  
      (Principal Executive Officer)  
         
    By: /s/ Sam Martin  
      Sam Martin  
      Senior Vice President and Chief Financial Officer  
      (Principal Financial Officer and Principal Accounting Officer)  

     

    KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Anthony S. Marucci and Sam Martin, and each of them singly, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

     

    -4-

     

     

    Signature   Title   Date
    /s/ ANTHONY S. MARUCCI   President, Chief Executive Officer, and Director   June 6, 2025
    Anthony S. Marucci   (Principal Executive Officer)    
             
    /s/ SAM MARTIN   Senior Vice President,   June 6, 2025
    Sam Martin   Chief Financial Officer and Treasurer
    (Principal Financial and Accounting Officer)
       
             
    /s/ HARRY H. PENNER, JR.   Director, Chair of the Board of Directors   June 6, 2025
    Harry H. Penner, Jr.        
             
    /s/ KEITH L. BROWNLIE   Director   June 6, 2025
    Keith L. Brownlie        
             
    /s/ CHERYL L. COHEN   Director   June 6, 2025
    Cheryl L. Cohen        
             
    /s/ HERBERT J. CONRAD   Director   June 6, 2025
    Herbert J. Conrad        
             
    /s/ RITA I. JAIN, M.D.   Director   June 6, 2025
    Rita I. Jain, M.D.        
             
    /s/ JAMES J. MARINO   Director   June 6, 2025
    James J. Marino        
             
    /s/ GARRY A. NEIL, M.D.   Director   June 6, 2025
    Garry A. Neil, M.D.        
             
    /s/ DENICE TORRES   Director   June 6, 2025
    Denice Torres        

     

    -5-

     

    Get the next $CLDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    9/30/2024$45.00Neutral
    Goldman
    9/27/2024Outperform → Peer Perform
    Wolfe Research
    6/18/2024$58.00Buy
    Stifel
    6/11/2024$51.00Outperform
    Wolfe Research
    More analyst ratings

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

      77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids),

      6/14/25 10:48:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

      Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0)48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1)KIT related tolerability events demonstrated to be reversible Enrollment to Phase 3 CSU trials ongoingCompany to host webcast today at 6:00 pm ET HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast c

      6/12/25 6:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

      HAMPTON, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12th at 6:00 pm ET to discuss the data. Phase 2 CSU 76 Week Efficacy and Tolerability Data Company Webcast and Conference CallDate & Time: Thursday, June 12th at 6:00 pm ET/11:00 pm BSTPresenters: Company representatives and Martin Metz, MD, Professor, Department of De

      6/10/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

      HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors. "We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization." Ms. Torres added, "

      6/6/25 8:01:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

      2/16/23 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

      NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin

      2/21/22 12:00:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care